{"meta":{"query_hash":"5858a2241443","filters":{"venue":"Clinical Medicine Insights Therapeutics"},"cohort_total":15,"direct_labels_cover":0,"predictions_cover":15,"exported":15,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5858a2241443","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Medicine+Insights+Therapeutics"},"results":[{"id":"W1965329525","doi":"10.4137/cmt.s4012","title":"Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Provincial Laboratory of Public Health; University of Alberta","funders":"","keywords":"Varenicline; Smoking cessation; Medicine; Comorbidity; Psychiatry; Mental illness; Addiction; Nicotine replacement therapy; Pharmacotherapy; Nicotine; Tolerability; Mental health; Internal medicine; Adverse effect","score_opus":0.05322821542743384,"score_gpt":0.37534411572994764,"score_spread":0.3221159003025138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965329525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8755713,0.07781898,0.001997357,0.010871291,0.0006182262,0.00036314764,0.0007431056,0.0004809005,0.03153563],"genre_scores_gemma":[0.9728741,0.017116433,0.0019103687,0.0028909903,0.0004997561,0.000062991865,0.0005424385,0.000011767099,0.004091205],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998987,0.000035247933,0.000015229736,0.000015625343,0.000019888152,0.000015272642],"domain_scores_gemma":[0.99983287,0.000023242757,0.000052771105,0.000005969895,0.0000129097625,0.00007222702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024067386,0.00018837758,0.000487492,0.0001571453,0.00018918417,0.0002512196,0.0002337096,0.000667255,0.0039680596],"category_scores_gemma":[0.0006142992,0.000081174905,0.00021524557,0.0002512735,0.0000764775,0.00023651456,0.00019482577,0.00061543577,0.00090441527],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015217052,0.0031253558,0.05505145,0.001696626,0.00034461453,0.002395624,0.00013906183,0.00021450993,0.023755686,0.0006827599,0.012920064,0.8844571],"study_design_scores_gemma":[0.0125553,0.044156794,0.7772655,0.0010409558,0.0010689116,0.033448234,0.0003530552,0.0028177628,0.009532945,0.0014158719,0.11624115,0.00010355086],"about_ca_topic_score_codex":0.00037752022,"about_ca_topic_score_gemma":0.0017224754,"teacher_disagreement_score":0.0039680596,"about_ca_system_score_codex":0.00013209537,"about_ca_system_score_gemma":0.00028676412,"threshold_uncertainty_score":0.013274491},"labels":[],"label_agreement":null},{"id":"W1981981010","doi":"10.4137/cmt.s5884","title":"Efficacy and Safety of Galantamine Hydrobromide in the Treatment of Mild to Moderate Dementia","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Galantamine; Dementia; Mood; Placebo; Medicine; Nausea; Psychiatry; Disease; Internal medicine; Donepezil; Alternative medicine","score_opus":0.08946186334557535,"score_gpt":0.4202218599304458,"score_spread":0.33075999658487043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981981010","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02145736,0.97475433,0.0010529263,0.0004421372,0.00029825288,0.0012133308,0.00027073998,0.000028445278,0.00048239177],"genre_scores_gemma":[0.45898518,0.52881396,0.006184065,0.0015521721,0.0005684526,0.002934412,0.00043900937,0.000025325045,0.0004973404],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9804802,0.011968244,0.004581983,0.0009453576,0.001707754,0.00031642072],"domain_scores_gemma":[0.978617,0.015806364,0.0037145347,0.0005243234,0.0010953285,0.0002424545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026015464,0.0019573588,0.012706001,0.005218598,0.0005474104,0.0023815641,0.0013563747,0.0020783767,0.0019102014],"category_scores_gemma":[0.041991442,0.0013595795,0.02416805,0.0031346658,0.0007519872,0.0012329139,0.0011224995,0.0013527496,0.00017858486],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019508198,0.00017002384,0.0035199565,0.34383464,0.5903052,0.00024102036,0.00014966578,0.00075233256,0.0009775942,0.00023636287,0.00047994027,0.039825074],"study_design_scores_gemma":[0.01193757,0.0046615014,0.0056621153,0.027190449,0.9460307,0.00028229467,0.00007864273,0.00037251133,0.00062133116,0.000539643,0.002578772,0.000044402776],"about_ca_topic_score_codex":0.0025432366,"about_ca_topic_score_gemma":0.0066654896,"teacher_disagreement_score":0.026015464,"about_ca_system_score_codex":0.0022098687,"about_ca_system_score_gemma":0.0029567515,"threshold_uncertainty_score":0.13758457},"labels":[],"label_agreement":null},{"id":"W1989502045","doi":"10.4137/cmt.s3783","title":"Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lapatinib; Trastuzumab; Breast cancer; Cancer research; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Metastatic breast cancer; Cancer; Targeted therapy; Pertuzumab; Letrozole; Oncology; Internal medicine; Receptor; Tamoxifen","score_opus":0.18813864389023785,"score_gpt":0.4205964844946525,"score_spread":0.23245784060441463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989502045","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057740666,0.9065737,0.0061784224,0.011393613,0.0009187723,0.00008223692,0.000075614036,0.00016477756,0.016872212],"genre_scores_gemma":[0.32526556,0.6409555,0.00881838,0.0050871572,0.0023859392,0.000102232036,0.00023386956,0.000027291931,0.017124115],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988484,0.000040460374,0.000009618837,0.000012479864,0.00003361975,0.000018885969],"domain_scores_gemma":[0.9999368,0.000023225897,0.000010257078,0.0000019586266,0.00001049266,0.000017267792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005209575,0.0002636867,0.00035078137,0.00028139562,0.00012407513,0.0004870361,0.0002903806,0.0006442088,0.0010507171],"category_scores_gemma":[0.00027774772,0.000088027075,0.00017139234,0.00024787465,0.00020703272,0.00064851384,0.00027271072,0.0008231355,0.000418749],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010553853,0.00060039695,0.0012805292,0.0012603273,0.00004207518,0.0018348165,0.00014046625,0.00075523707,0.068114065,0.005163334,0.021295644,0.8984578],"study_design_scores_gemma":[0.002317633,0.011415652,0.010834665,0.00058291375,0.00032715278,0.031981893,0.0003027174,0.0045403955,0.12617745,0.006713665,0.80471003,0.00009573004],"about_ca_topic_score_codex":0.00014346505,"about_ca_topic_score_gemma":0.00063382095,"teacher_disagreement_score":0.0010507171,"about_ca_system_score_codex":0.00034099078,"about_ca_system_score_gemma":0.0002516528,"threshold_uncertainty_score":0.003515005},"labels":[],"label_agreement":null},{"id":"W2005153650","doi":"10.4137/cmt.s3567","title":"Risperidone for Individuals with Refractory Schizophrenia","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Risperidone; Schizophrenia (object-oriented programming); Refractory (planetary science); Antipsychotic; Clozapine; Psychiatry; Atypical antipsychotic; Medicine; Psychology","score_opus":0.08233823778095527,"score_gpt":0.40706287697328014,"score_spread":0.32472463919232486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005153650","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013724421,0.9767616,0.00015910414,0.002540978,0.00027209843,0.00008395041,0.00017453436,0.000019478151,0.0062638023],"genre_scores_gemma":[0.21625741,0.7752141,0.0015220226,0.0038079137,0.0007892856,0.0001768883,0.00028535965,0.0000068394866,0.0019401958],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993801,0.00032295284,0.00014636709,0.000027337086,0.00009802436,0.000025052545],"domain_scores_gemma":[0.9983607,0.00090635096,0.0005419144,0.000022209952,0.000097559714,0.000071267394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096949236,0.00023413025,0.0006342276,0.0012529107,0.00017568677,0.0003406032,0.00021307234,0.0005841024,0.0020756016],"category_scores_gemma":[0.0035483472,0.00010381213,0.00070170214,0.000779036,0.00020797945,0.0002878118,0.00024707994,0.00031666626,0.00040114054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002244661,0.00012207664,0.0058886954,0.09842727,0.0011715632,0.0039301026,0.00059776957,0.00015810599,0.0023056008,0.0010271486,0.026627794,0.8574991],"study_design_scores_gemma":[0.006076949,0.0064019705,0.1224894,0.12062639,0.010354134,0.035996374,0.0019468158,0.0004913204,0.004293567,0.005859045,0.685328,0.00013592611],"about_ca_topic_score_codex":0.0013930863,"about_ca_topic_score_gemma":0.0058544073,"teacher_disagreement_score":0.0020756016,"about_ca_system_score_codex":0.00047576314,"about_ca_system_score_gemma":0.001491898,"threshold_uncertainty_score":0.006943643},"labels":[],"label_agreement":null},{"id":"W2007434442","doi":"10.4137/cmt.s4670","title":"Effectiveness and Safety of Rizatriptan Benzoate 10 mg in the Treatment of Migraine Headaches","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; GDI Integrated Facility Services (Canada); Merck Canada Inc. (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Rizatriptan; Medicine; Migraine; Nausea; Headaches; Somnolence; Adverse effect; Anesthesia; Triptans; Prospective cohort study; Internal medicine; Sumatriptan; Surgery","score_opus":0.09138714600609213,"score_gpt":0.407207713880599,"score_spread":0.31582056787450685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007434442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996181,0.0030262168,0.00008348061,0.000058134647,0.000013735323,0.00007005212,0.00014690074,0.000012018211,0.000408363],"genre_scores_gemma":[0.99776924,0.0014130431,0.00018955901,0.000076812226,0.000046423276,0.000050069833,0.00024543444,0.0000024734404,0.00020692816],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99956506,0.0001810959,0.000044278757,0.000054692555,0.00010762852,0.00004722398],"domain_scores_gemma":[0.9994647,0.00015774548,0.00025536073,0.00002567481,0.000022590233,0.000073877934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007622626,0.00023402847,0.0005901896,0.000206306,0.000115295945,0.00030391247,0.00024355657,0.00030388727,0.0009199967],"category_scores_gemma":[0.0010172911,0.00012828202,0.00046736927,0.00015176984,0.00023177192,0.00020157517,0.00012777283,0.00042846304,0.00022233302],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28871092,0.015196776,0.097663075,0.0011412483,0.0018409707,0.0005823797,0.0002587103,0.0018986469,0.121459976,0.00011921819,0.0011209071,0.47000712],"study_design_scores_gemma":[0.047792267,0.4846096,0.44836628,0.00009353751,0.0011955333,0.0014677318,0.000093894116,0.0014108066,0.011883873,0.000094360716,0.0029467782,0.000045368644],"about_ca_topic_score_codex":0.00042806272,"about_ca_topic_score_gemma":0.0008851624,"teacher_disagreement_score":0.0009199967,"about_ca_system_score_codex":0.00022059522,"about_ca_system_score_gemma":0.00029333704,"threshold_uncertainty_score":0.0040313005},"labels":[],"label_agreement":null},{"id":"W2013609844","doi":"10.4137/cmt.s4500","title":"Gastric Acid-Related Diseases: Focus on Esomeprazole","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Esomeprazole; Omeprazole; Medicine; Rabeprazole; Gastroenterology; Proton-pump inhibitor; Clopidogrel; Internal medicine; Gastric acid; Famotidine; Helicobacter pylori; Aspirin; Stomach","score_opus":0.04990391487098689,"score_gpt":0.3820149494845545,"score_spread":0.3321110346135676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013609844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028083532,0.9473093,0.0006478222,0.016848586,0.0039973166,0.000016702896,0.000040604078,0.000033671084,0.028297601],"genre_scores_gemma":[0.01951265,0.92524326,0.000903292,0.009475256,0.032242607,0.000016686481,0.0000634868,0.000024969357,0.012517769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997371,0.00006869721,0.000027392816,0.00004747484,0.000081094535,0.000038280672],"domain_scores_gemma":[0.9990101,0.00044483194,0.000059178088,0.000037621336,0.00029728064,0.00015098718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057344144,0.0005800989,0.0011765127,0.0014215464,0.00028798278,0.0011989019,0.00041700184,0.0018154944,0.011124116],"category_scores_gemma":[0.0008526999,0.00017562095,0.00042134788,0.0010771423,0.00072378287,0.0021942828,0.0008214254,0.0016818861,0.0036451642],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037127064,0.00030227817,0.004571875,0.005778138,0.00016046189,0.005609381,0.00024125451,0.00023082066,0.004246367,0.008753895,0.12626782,0.8434664],"study_design_scores_gemma":[0.0000792647,0.00041221583,0.01661367,0.003297945,0.00021265281,0.030459384,0.00032640333,0.00036808904,0.00076260883,0.0049397,0.9424883,0.00003965063],"about_ca_topic_score_codex":0.00093522045,"about_ca_topic_score_gemma":0.0027352662,"teacher_disagreement_score":0.011124116,"about_ca_system_score_codex":0.0005363574,"about_ca_system_score_gemma":0.0005835206,"threshold_uncertainty_score":0.037213862},"labels":[],"label_agreement":null},{"id":"W2015849975","doi":"10.4137/cmt.s7586","title":"Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"","keywords":"Mitoxantrone; Medicine; Cardiotoxicity; Multiple sclerosis; Tolerability; Internal medicine; Oncology; Ejection fraction; Natalizumab; Disease; Adverse effect; Chemotherapy; Heart failure; Immunology","score_opus":0.3327976076464534,"score_gpt":0.39962326133547466,"score_spread":0.06682565368902127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015849975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988416,0.0004625031,0.00015474047,0.000010015995,0.0000035366975,0.00008219458,0.00003438036,0.0000055981077,0.00040543184],"genre_scores_gemma":[0.99964845,0.00007511507,0.000101054764,0.000011108686,0.0000055236965,0.00001902317,0.000038811635,6.7962424e-7,0.00010023287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999658,0.0001724852,0.000034743378,0.000040541487,0.000059433838,0.000034678098],"domain_scores_gemma":[0.99930346,0.00022280028,0.00021549758,0.00005786359,0.000076780314,0.00012347494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011032725,0.00026628384,0.00049226655,0.00035624346,0.00019433578,0.00015708224,0.00016284228,0.00029516726,0.0017368847],"category_scores_gemma":[0.0011354949,0.00010306005,0.00023336447,0.00021656614,0.00026512082,0.00016882684,0.00016854022,0.00042820926,0.00016543762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08996353,0.006582481,0.50517744,0.0009950203,0.0004117954,0.011616484,0.00061080744,0.000513531,0.31816778,0.00016683362,0.0004591334,0.06533518],"study_design_scores_gemma":[0.0016134076,0.10951931,0.83431494,0.000029717048,0.00029826546,0.01310437,0.00013758017,0.00061652187,0.039378677,0.000074578165,0.0008992949,0.00001334126],"about_ca_topic_score_codex":0.0002636417,"about_ca_topic_score_gemma":0.00035045113,"teacher_disagreement_score":0.0017368847,"about_ca_system_score_codex":0.00017713419,"about_ca_system_score_gemma":0.00014409599,"threshold_uncertainty_score":0.0058346987},"labels":[],"label_agreement":null},{"id":"W2029911300","doi":"10.4137/cmt.s2213","title":"Emerging Therapies for the Management of Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada); Health Sciences Centre","funders":"","keywords":"Medicine; Multiple sclerosis; Data extraction; Clinical trial; MEDLINE; Cochrane Library; Randomized controlled trial; Placebo; Transplantation; Intensive care medicine; Internal medicine; Alternative medicine; Pathology; Immunology","score_opus":0.27042793296101914,"score_gpt":0.44032114106798154,"score_spread":0.1698932081069624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029911300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027173283,0.9965359,0.00035499467,0.00067692593,0.0002912139,0.00019193914,0.00019620228,0.000013266427,0.0014677233],"genre_scores_gemma":[0.0032718284,0.99092495,0.0029471756,0.0014162309,0.00044072507,0.00039386522,0.0001657603,0.000006196559,0.00043337076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939632,0.0022712075,0.0018219025,0.00035524153,0.0014319244,0.00015650256],"domain_scores_gemma":[0.9906465,0.0053021433,0.002639754,0.00014327792,0.0011107209,0.00015769411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064974753,0.0012682913,0.002759127,0.00879401,0.00051146455,0.0023921314,0.0014555217,0.0020582948,0.012749311],"category_scores_gemma":[0.014215935,0.00032328576,0.002103383,0.006008959,0.0006089572,0.0025365152,0.0013078712,0.0016431209,0.001684386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004650485,0.0001009954,0.0006614789,0.42578197,0.0014013936,0.00034952041,0.00022146257,0.00030731628,0.0007489232,0.003539755,0.01511211,0.55131006],"study_design_scores_gemma":[0.00060187693,0.0006893357,0.0038988334,0.6962663,0.005238214,0.0022126334,0.0004584011,0.00028092085,0.00075008016,0.0034940832,0.28606004,0.000049233626],"about_ca_topic_score_codex":0.0012678064,"about_ca_topic_score_gemma":0.0038083873,"teacher_disagreement_score":0.012749311,"about_ca_system_score_codex":0.0018640688,"about_ca_system_score_gemma":0.0042742454,"threshold_uncertainty_score":0.0426507},"labels":[],"label_agreement":null},{"id":"W2049767450","doi":"10.4137/cmt.s4120","title":"Intranasal Ciclesonide in Allergic Rhinitis","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ciclesonide; Medicine; Nasal administration; Nasal spray; Asthma; Dermatology; Immunology; Inhaled corticosteroids","score_opus":0.07250437245537755,"score_gpt":0.37392661891136175,"score_spread":0.3014222464559842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049767450","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011457746,0.97942024,0.000505351,0.0009894854,0.00046920366,0.000024479079,0.00002097594,0.000024809238,0.0070876526],"genre_scores_gemma":[0.13514994,0.8502274,0.0014609109,0.001388404,0.0012980346,0.00004504748,0.0000728718,0.000009125482,0.010348331],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998129,0.00006003784,0.000023462682,0.000020856542,0.00006601411,0.000016759981],"domain_scores_gemma":[0.99987316,0.000042117805,0.000033752647,0.0000072221414,0.000028311177,0.000015369886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035461193,0.00025594616,0.0005893414,0.0003894457,0.00016536665,0.0003101131,0.00021018369,0.00054603885,0.0025169763],"category_scores_gemma":[0.00036230794,0.00006879921,0.00021398198,0.0003508884,0.00018321139,0.0002704619,0.00021139703,0.00069062214,0.0011380331],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060482376,0.00027066193,0.0009673933,0.004261124,0.00008121166,0.0022152036,0.00008961364,0.00008865903,0.017318944,0.0008969432,0.0095890835,0.9636164],"study_design_scores_gemma":[0.0007265137,0.006794957,0.037083644,0.0034213425,0.0008248927,0.05050084,0.00033844038,0.00038955474,0.02193928,0.0025445148,0.8753786,0.00005747533],"about_ca_topic_score_codex":0.0005930493,"about_ca_topic_score_gemma":0.0015852835,"teacher_disagreement_score":0.0025169763,"about_ca_system_score_codex":0.00020492755,"about_ca_system_score_gemma":0.00032932626,"threshold_uncertainty_score":0.008420169},"labels":[],"label_agreement":null},{"id":"W2069864063","doi":"10.4137/cmt.s11675","title":"Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bedaquiline; Tuberculosis; Multiple drug resistance; Isoniazid; Antibiotics; Drug resistance; Internal medicine; Intensive care medicine; Clinical trial; Incidence (geometry); Mycobacterium tuberculosis; Microbiology; Pathology; Biology","score_opus":0.10248851677833781,"score_gpt":0.41540600339063316,"score_spread":0.31291748661229535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069864063","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.249761,0.7258255,0.0028791244,0.0036610505,0.00051544054,0.00030300752,0.001191612,0.00013689097,0.015726428],"genre_scores_gemma":[0.8362426,0.15563312,0.0026210775,0.0017350437,0.0003839354,0.00012857215,0.00082960696,0.00002408516,0.0024019983],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994203,0.00026521742,0.0000759019,0.0000653102,0.00014544223,0.000027894535],"domain_scores_gemma":[0.9993349,0.00024643756,0.00021739164,0.000030247378,0.000103980485,0.00006705928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013816535,0.00017425616,0.00061997835,0.00032850943,0.00017742442,0.00045433562,0.00050330244,0.00041110418,0.0024108044],"category_scores_gemma":[0.0017663732,0.00008283787,0.00045164116,0.00028243393,0.0003425525,0.00043454661,0.00031299336,0.00087840436,0.00042236838],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132689485,0.0008447981,0.0068120123,0.0047000623,0.00036569155,0.0005917984,0.00021039169,0.00044165837,0.021894882,0.0013038818,0.0033211242,0.9462447],"study_design_scores_gemma":[0.01757446,0.15445955,0.2060755,0.0052705896,0.002977751,0.02411093,0.0012052407,0.0034449925,0.09453175,0.004069156,0.48601976,0.0002603207],"about_ca_topic_score_codex":0.0004195257,"about_ca_topic_score_gemma":0.00077747414,"teacher_disagreement_score":0.0024108044,"about_ca_system_score_codex":0.0003039904,"about_ca_system_score_gemma":0.0004158938,"threshold_uncertainty_score":0.008064926},"labels":[],"label_agreement":null},{"id":"W2084281139","doi":"10.4137/cmt.s4456","title":"Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Carboplatin; Ovarian cancer; Doxorubicin; Paclitaxel; Drug; Oncology; Pharmacology; Internal medicine; Cancer; Chemotherapy; Cisplatin","score_opus":0.08930760328561985,"score_gpt":0.4170289362062235,"score_spread":0.3277213329206037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084281139","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019267013,0.9696632,0.0023368367,0.0025527226,0.00045801257,0.000037830643,0.000033291693,0.000028020599,0.005623122],"genre_scores_gemma":[0.16143228,0.8279808,0.0032891731,0.0012374447,0.0009351908,0.000052835036,0.00010817076,0.00001386504,0.0049502226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99993443,0.000021954498,0.000008664167,0.000009554382,0.000019545476,0.0000057874927],"domain_scores_gemma":[0.9999378,0.000023761473,0.000016643058,0.0000030310673,0.000007725161,0.000011038504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003597073,0.00015501252,0.00021616614,0.00039591247,0.00006498917,0.00020773707,0.00015433674,0.00032862218,0.00070509606],"category_scores_gemma":[0.00031529772,0.00005902116,0.0000840377,0.00027906854,0.00018755245,0.0002909115,0.0002183915,0.00049715996,0.0003202894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067679764,0.00010321875,0.0006903464,0.0015491669,0.00003761301,0.00085265917,0.000086914435,0.0007680108,0.01327769,0.002931082,0.0061357366,0.9728908],"study_design_scores_gemma":[0.0006771212,0.0037509482,0.011191467,0.0014928146,0.00015570373,0.013632476,0.00011997694,0.0021332277,0.022438012,0.0048526363,0.9395069,0.00004876105],"about_ca_topic_score_codex":0.00028837405,"about_ca_topic_score_gemma":0.0004644124,"teacher_disagreement_score":0.00070509606,"about_ca_system_score_codex":0.00031029794,"about_ca_system_score_gemma":0.00022299583,"threshold_uncertainty_score":0.0023587942},"labels":[],"label_agreement":null},{"id":"W2275755947","doi":"10.4137/cmt.s18886","title":"Stroke Prevention with Percutaneous Left Atrial Appendage Closure","year":2016,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Atrial fibrillation; Left atrial appendage occlusion; Percutaneous; Stroke (engine); Cardiology; Internal medicine; Thrombus; Occlusion; Thromboembolic stroke; Atrial Appendage; Thrombosis; Warfarin","score_opus":0.15231308163768636,"score_gpt":0.4183604860180196,"score_spread":0.26604740438033325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275755947","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07445379,0.79955834,0.016325628,0.01599343,0.0028210594,0.0003865668,0.00045351006,0.0004828363,0.08952475],"genre_scores_gemma":[0.6109012,0.34985405,0.013410499,0.005044387,0.009754326,0.0003802209,0.0007607113,0.00007757693,0.009817048],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950933,0.00013150409,0.00007806584,0.000066699744,0.00016641313,0.000047965757],"domain_scores_gemma":[0.9995322,0.00014921246,0.00016851081,0.000023254834,0.00006558417,0.00006128481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044708245,0.0002624064,0.00073942606,0.0007989099,0.0003130641,0.0007495304,0.00024301172,0.00041560546,0.0052769817],"category_scores_gemma":[0.0022526423,0.00007351566,0.00086788705,0.00044252438,0.00024247453,0.0005076525,0.00043471524,0.0009557228,0.00084824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007729417,0.00078394846,0.0076445667,0.0029539613,0.00043256354,0.0013834115,0.00011029223,0.0002905891,0.0021905077,0.0028263621,0.011955872,0.96865493],"study_design_scores_gemma":[0.0052021546,0.021358827,0.23867814,0.020399772,0.0037664308,0.06818704,0.00078765256,0.0028514238,0.015278067,0.04244938,0.58085597,0.00018520307],"about_ca_topic_score_codex":0.00033344497,"about_ca_topic_score_gemma":0.0004628742,"teacher_disagreement_score":0.0052769817,"about_ca_system_score_codex":0.00024371735,"about_ca_system_score_gemma":0.0005509447,"threshold_uncertainty_score":0.017653227},"labels":[],"label_agreement":null},{"id":"W2759644066","doi":"10.1177/1179559x17731801","title":"Brexpiprazole in the Treatment of Major Depressive Disorder","year":2017,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network; St. Michael's Hospital","funders":"Ontario Brain Institute; Massachusetts General Hospital","keywords":"Partial agonist; Aripiprazole; PsycINFO; Major depressive disorder; Adjunctive treatment; Antipsychotic; Antidepressant; Medicine; Meta-analysis; Psychology; Atypical antipsychotic; Psychiatry; Psychotherapist; MEDLINE; Schizophrenia (object-oriented programming); Agonist; Internal medicine; Anxiety; Mood; Receptor","score_opus":0.1311998809784387,"score_gpt":0.4398751764897023,"score_spread":0.3086752955112636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759644066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002555336,0.9966336,0.000040349816,0.00023068655,0.000041723306,0.000016874614,0.000040144852,0.0000034718444,0.00043777993],"genre_scores_gemma":[0.029653523,0.96912897,0.00031389354,0.0005047572,0.00008662899,0.000027590997,0.000067400106,0.0000011871148,0.0002160412],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993666,0.00026207196,0.00017055754,0.000052927644,0.00012511108,0.000022728753],"domain_scores_gemma":[0.99925584,0.0003994336,0.00022912247,0.000010437785,0.000083604,0.000021624397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094824814,0.00023958016,0.0008855078,0.0010577565,0.00011552705,0.00043693127,0.00033959467,0.0005086501,0.0019077429],"category_scores_gemma":[0.0019644343,0.00012635464,0.0007288206,0.001044191,0.00016092315,0.00031921547,0.00025761017,0.00040990885,0.0002103571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002281329,0.000098585035,0.0010450584,0.201578,0.0024912916,0.00033436186,0.0001436349,0.00016238849,0.002405988,0.00046221717,0.005247341,0.78374976],"study_design_scores_gemma":[0.009394899,0.011402823,0.08228474,0.38822806,0.068313174,0.008072429,0.001200046,0.0014336067,0.0068284487,0.0025390189,0.42016274,0.0001400183],"about_ca_topic_score_codex":0.0011523156,"about_ca_topic_score_gemma":0.004588435,"teacher_disagreement_score":0.0019077429,"about_ca_system_score_codex":0.00030535416,"about_ca_system_score_gemma":0.0007319347,"threshold_uncertainty_score":0.0063819885},"labels":[],"label_agreement":null},{"id":"W2761151032","doi":"10.1177/1179559x17734227","title":"Efficacy of Continuous Positive Airway Pressure Treatment in Patients with Cardiac Arrhythmia and Obstructive Sleep Apnea: What is the Evidence?","year":2017,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Obstructive Sleep Apnea Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Toronto Rehabilitation Institute; Sunnybrook Health Science Centre; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Continuous positive airway pressure; Obstructive sleep apnea; Cardiology; Cardiac arrhythmia; Internal medicine; Observational study; Heart failure; Positive airway pressure; Ejection fraction; Confounding; Coronary artery disease; Sleep apnea; Intensive care medicine; Atrial fibrillation","score_opus":0.051850662150654536,"score_gpt":0.36904719783004464,"score_spread":0.3171965356793901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761151032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014783392,0.9967507,0.000053008556,0.00082813675,0.00021627314,0.000060362643,0.00020253992,0.000003783449,0.00040685653],"genre_scores_gemma":[0.042635843,0.95180124,0.00060513144,0.0026329728,0.001462829,0.00025765918,0.00047933147,0.000009395498,0.00011559047],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98930335,0.003467266,0.0046869647,0.0008182053,0.0015207831,0.00020346744],"domain_scores_gemma":[0.917969,0.06475112,0.0114549855,0.0009823383,0.0041645234,0.0006780685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011149422,0.00083532947,0.009077613,0.0037271457,0.000565422,0.0028946593,0.00272646,0.004309525,0.005051011],"category_scores_gemma":[0.059230153,0.0007827365,0.006668195,0.0047243987,0.0011735321,0.0029265317,0.0008627184,0.0019808656,0.0006163991],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028586679,0.00026244746,0.0063093025,0.81171364,0.018743856,0.00014415398,0.00016492383,0.00009915556,0.00021066317,0.00048084292,0.002814234,0.15619814],"study_design_scores_gemma":[0.0027432353,0.0021405495,0.0415983,0.81197494,0.10518356,0.00082802784,0.0006477052,0.00025056876,0.00040080352,0.0011467001,0.03297383,0.00011183527],"about_ca_topic_score_codex":0.0026663241,"about_ca_topic_score_gemma":0.004802956,"teacher_disagreement_score":0.011149422,"about_ca_system_score_codex":0.001772924,"about_ca_system_score_gemma":0.0033876528,"threshold_uncertainty_score":0.05896449},"labels":[],"label_agreement":null},{"id":"W96046762","doi":"10.4137/cmt.s9566","title":"Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Polycythaemia; Medicine; Food and drug administration; Clinical trial; Janus kinase; Janus kinase 2; Internal medicine; Pharmacology; Bone marrow","score_opus":0.15977028268133486,"score_gpt":0.4327420877786614,"score_spread":0.27297180509732655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W96046762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026911686,0.9969422,0.00016328336,0.0006563353,0.00025160323,0.0000055086643,0.000014633617,0.000007223642,0.001690169],"genre_scores_gemma":[0.0016646638,0.99562585,0.0003975911,0.00069014716,0.000662843,0.000009318798,0.000038666145,0.0000033164108,0.00090744224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997713,0.00006483554,0.00004061187,0.000036957998,0.00007075119,0.000015468411],"domain_scores_gemma":[0.99951255,0.0002918067,0.000075402124,0.000010812166,0.000070776674,0.00003858001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005553084,0.0006204105,0.0014789687,0.0018527058,0.00022655075,0.00065017707,0.00075270666,0.0007109119,0.0042204447],"category_scores_gemma":[0.00077768083,0.00018856628,0.0005847165,0.0016992019,0.0003020122,0.0011014784,0.00034926407,0.001506056,0.0016754438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001319121,0.000091104404,0.00020975056,0.009058848,0.0001238338,0.0006728822,0.000043417676,0.00036364605,0.0014557089,0.0016089496,0.04026796,0.94597197],"study_design_scores_gemma":[0.000074764146,0.0002472525,0.0016848529,0.0068647163,0.0002114415,0.0064000045,0.00005814292,0.00018722231,0.0004968759,0.001251159,0.98250145,0.000022181892],"about_ca_topic_score_codex":0.00048087878,"about_ca_topic_score_gemma":0.0014927563,"teacher_disagreement_score":0.0042204447,"about_ca_system_score_codex":0.0004459522,"about_ca_system_score_gemma":0.0005053347,"threshold_uncertainty_score":0.01411885},"labels":[],"label_agreement":null}]}